WO2007074238A3 - Nouveaux derives de n-alk-(e)-ylidene-n'-pyrimidin-2-yl-hydrazines et leurs utilisations comme medicaments cytoprotecteurs - Google Patents

Nouveaux derives de n-alk-(e)-ylidene-n'-pyrimidin-2-yl-hydrazines et leurs utilisations comme medicaments cytoprotecteurs Download PDF

Info

Publication number
WO2007074238A3
WO2007074238A3 PCT/FR2006/002867 FR2006002867W WO2007074238A3 WO 2007074238 A3 WO2007074238 A3 WO 2007074238A3 FR 2006002867 W FR2006002867 W FR 2006002867W WO 2007074238 A3 WO2007074238 A3 WO 2007074238A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
ylidene
alk
pyrimidin
cytoprotective
Prior art date
Application number
PCT/FR2006/002867
Other languages
English (en)
Other versions
WO2007074238A2 (fr
Inventor
Nathalie Compagnone
Corinne Chaimbault
Cyrille Drouot
Laure Jamot
Original Assignee
Trophos
Nathalie Compagnone
Corinne Chaimbault
Cyrille Drouot
Laure Jamot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophos, Nathalie Compagnone, Corinne Chaimbault, Cyrille Drouot, Laure Jamot filed Critical Trophos
Publication of WO2007074238A2 publication Critical patent/WO2007074238A2/fr
Publication of WO2007074238A3 publication Critical patent/WO2007074238A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se place dans le domaine de la pharmacie, particulièrement dans le domaine de la cytoprotection, avantageusement dans les domaines de la cardioprotection et de la neuroprotection. Plus particulièrement elle concerne une famille de composés chimiques, dérivés de N-alk-(E)-ylidène-N'- pyrimidin-2-yl-hydrazines, pour lesquels une activité cytoprotectrice, particulièrement neuroprotectrice ou cardioprotectrice a pu être démontrée. La présente invention concerne donc l'utilisation desdits composés chimiques à titre de médicaments, notamment comme médicaments cytoprotecteurs, particulièrement comme médicaments cardioprotecteurs ou neuroprotecteurs. L'invention concerne également les compositions pharmaceutiques renfermant lesdits composés, certains composés nouveaux, leurs procédés de synthèse ainsi que certains intermédiaires de synthèse eux-mêmes nouveaux.
PCT/FR2006/002867 2005-12-28 2006-12-26 Nouveaux derives de n-alk-(e)-ylidene-n'-pyrimidin-2-yl-hydrazines et leurs utilisations comme medicaments cytoprotecteurs WO2007074238A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0513410 2005-12-28
FR0513410A FR2895407A1 (fr) 2005-12-28 2005-12-28 Nouveaux derives de n-alk-(e)-ylidene-n'-pyrimidin-2-yl- hydrazines et leurs utilisations comme medicament

Publications (2)

Publication Number Publication Date
WO2007074238A2 WO2007074238A2 (fr) 2007-07-05
WO2007074238A3 true WO2007074238A3 (fr) 2007-08-30

Family

ID=36693504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/002867 WO2007074238A2 (fr) 2005-12-28 2006-12-26 Nouveaux derives de n-alk-(e)-ylidene-n'-pyrimidin-2-yl-hydrazines et leurs utilisations comme medicaments cytoprotecteurs

Country Status (2)

Country Link
FR (1) FR2895407A1 (fr)
WO (1) WO2007074238A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10723706B2 (en) * 2016-06-13 2020-07-28 Ramot At Tel-Aviv University Ltd. Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
WO2022146324A1 (fr) * 2020-12-29 2022-07-07 T.C. Erci̇yes Üni̇versi̇tesi̇ Synthèse de dérivés de pyrimidine-4(1h)-one à partir d'hydrazineylidène nouveau

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063196A1 (fr) * 2003-01-14 2004-07-29 De Novo Pharmaceuticals Limited Composes 1,2,4-triazin-3-yl-hydrazine ou 5h-1,2,4-triazino[5,6-b]indol-3-yl-hydrazine utilises comme inhibiteurs de bace utiles dans le traitement de la maladie d'alzheimer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063196A1 (fr) * 2003-01-14 2004-07-29 De Novo Pharmaceuticals Limited Composes 1,2,4-triazin-3-yl-hydrazine ou 5h-1,2,4-triazino[5,6-b]indol-3-yl-hydrazine utilises comme inhibiteurs de bace utiles dans le traitement de la maladie d'alzheimer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BADDAR ET AL.: "Acetylenic ketones. Part V (1).", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 15, no. 1, 1978, pages 105 - 112 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002393020, retrieved from STN Database accession no. 2001:77550 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002393021, retrieved from STN Database accession no. 1978:190730 *
DATABASE CHEMCATS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002393019, retrieved from STN *

Also Published As

Publication number Publication date
FR2895407A1 (fr) 2007-06-29
WO2007074238A2 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2007009109A3 (fr) Composes antiviraux
WO2007045462A3 (fr) Nouveaux ligands du recepteur vanilloide et leur utilisation dans la production de medicaments
WO2008070462A3 (fr) N-oxydes d'analogues 4,5-époxy-morphinanium
WO2008064353A3 (fr) Analogues 4,5-époxy-morphinanium saturé en position 7 et 8
HK1113790A1 (en) Selurampanel
WO2006127899A3 (fr) Synthese de (r)-n-methylnaltrexone
WO2010012904A3 (fr) Nouveaux dérivés de l'oxime de cholest-4-èn-3-one, compositions pharmaceutiques les renfermant, et procédé de préparation
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
WO2006100082A3 (fr) Derives d'oxindole substitues, medicaments contenant ces derives et leur utilisation
WO2007065595A3 (fr) Derives de la xanthine, procedes de preparation et utilisations de ceux-ci
TW200745039A (en) Isotopically substituted pantoprazole
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
WO2007098124A3 (fr) Procédés pour la synthèse convergente de dérivés de la calichéamicine
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
TN2010000045A1 (en) Novel herbicides
WO2006133006A3 (fr) 1-methyl-1h-pyrazole-4-carboxamides utiles comme agents chimiotherapeutiques anticancereux
WO2005097787A3 (fr) Derives de benzothiazoles capables de moduler l’activite des cdk et leur utilisation comme agents anticancereux
WO2007016029A3 (fr) Diazepinoquinolines, synthese de ces dernieres et intermediaires correspondants
WO2007002722A3 (fr) Procédé de purification d'un intermédiaire de l'anastrozole
AU2006243194A8 (en) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
WO2007027742A3 (fr) Antagonistes de l'integrine $g(a)2$g(b)1/gpia-iia a petites molecules
WO2006122777A3 (fr) Utilisation de derives de thiazol-4-one 2,5-disubstitues dans des medicaments
WO2008074693A3 (fr) Procédé de préparation de 3,5-di-omicron-acyl-2-fluoro-2-c-méthyl-d-ribono-gamma-lactone
WO2007074238A3 (fr) Nouveaux derives de n-alk-(e)-ylidene-n'-pyrimidin-2-yl-hydrazines et leurs utilisations comme medicaments cytoprotecteurs
WO2007003767A3 (fr) Nouveaux composes chimiques et leurs utilisations comme medicament pour des maladies neurodegeneratives

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06847137

Country of ref document: EP

Kind code of ref document: A2